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Abstract
Background: There is limited evidence on the optimal timing of antiretroviral therapy (ART) initiation in children 2–5 y of
age. We conducted a causal modelling analysis using the International Epidemiologic Databases to Evaluate AIDS–Southern
Africa (IeDEA-SA) collaborative dataset to determine the difference in mortality when starting ART in children aged 2–5 y
immediately (irrespective of CD4 criteria), as recommended in the World Health Organization (WHO) 2013 guidelines,
compared to deferring to lower CD4 thresholds, for example, the WHO 2010 recommended threshold of CD4 count ,750
cells/mm3 or CD4 percentage (CD4%) ,25%.
Methods and Findings: ART-naı¨ve children enrolling in HIV care at IeDEA-SA sites who were between 24 and 59 mo of age
at first visit and with $1 visit prior to ART initiation and $1 follow-up visit were included. We estimated mortality for ART
initiation at different CD4 thresholds for up to 3 y using g-computation, adjusting for measured time-dependent
confounding of CD4 percent, CD4 count, and weight-for-age z-score. Confidence intervals were constructed using
bootstrapping. The median (first; third quartile) age at first visit of 2,934 children (51% male) included in the analysis was
3.3 y (2.6; 4.1), with a median (first; third quartile) CD4 count of 592 cells/mm3 (356; 895) and median (first; third quartile)
CD4% of 16% (10%; 23%). The estimated cumulative mortality after 3 y for ART initiation at different CD4 thresholds ranged
from 3.4% (95% CI: 2.1–6.5) (no ART) to 2.1% (95% CI: 1.3%–3.5%) (ART irrespective of CD4 value). Estimated mortality was
overall higher when initiating ART at lower CD4 values or not at all. There was no mortality difference between starting ART
immediately, irrespective of CD4 value, and ART initiation at the WHO 2010 recommended threshold of CD4 count ,750
cells/mm3 or CD4% ,25%, with mortality estimates of 2.1% (95% CI: 1.3%–3.5%) and 2.2% (95% CI: 1.4%–3.5%) after 3 y,
respectively. The analysis was limited by loss to follow-up and the unavailability of WHO staging data.
Conclusions: The results indicate no mortality difference for up to 3 y between ART initiation irrespective of CD4 value and
ART initiation at a threshold of CD4 count ,750 cells/mm3 or CD4% ,25%, but there are overall higher point estimates for
mortality when ART is initiated at lower CD4 values.
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Introduction
HIV infection continues to contribute substantially to the
burden of disease in children, with an estimated 330,000 new
paediatric infections worldwide in 2011. Paediatric antiretroviral
combination therapy (ART) is highly effective, but ART coverage
for children who need it was below 30% in 2011 [1]. Furthermore,
there is still limited evidence from randomized controlled trials
(RCTs) regarding the optimal timing of ART initiation in children
aged 2–5 y [2,3]. While earlier ART initiation may reduce
mortality and morbidity, it could also increase the risk of toxicity
and earlier development of drug resistance.
The Children with HIV Early Antiretroviral Therapy trial
demonstrated a 76% (95% CI: 49%–89%) reduction in mortality
associated with immediate compared to deferred ART in infants
less than 3 mo of age; however, results of studies in older children
are less clear [4–6]. The Pediatric Randomized to Early versus
Deferred Initiation in Cambodia and Thailand (PREDICT) trial
[7–9] enrolled children aged 1–12 y with initial CD4 percentage
(CD4%) values of 15%–24% without US Centers for Disease
Control and Prevention (CDC) category C disease. These
children were randomly assigned to start ART immediately or
defer therapy until their CD4% dropped below 15% or a CDC
category C event occurred. There was no difference between the
two arms in mortality, AIDS-free survival, number of new
category B and C events, neurodevelopmental outcomes, rate of
hospital admission, or number of drug-related adverse events
[7,9]. However, less than a third of the children included in the
trial (96 in total) were in the 2–5-y age group. This group may
experience more rapid disease progression than older children in
the absence of ART, and so the benefits of immediate ART
might be greater [10–12]. In addition, because of the low event
rate for the primary outcomes (five CDC category C events, one
death), the PREDICT study authors concluded that the study was
underpowered to detect a difference between the two random-
ization groups [9].
In the absence of evidence from RCTs, observational data from
cohort studies may be used to address this question. Such analyses
are not straightforward, however, because of time-dependent
confounding. The CD4 count, for example, is a time-dependent
confounder that varies with time, predicts the initiation of ART,
but also predicts the probability of dying. Causal modelling
techniques such as g-computation enable estimation of the causal
effect of an intervention on an outcome, taking into account such
time-dependent confounding [13–15]. We used data from the
International Epidemiologic Databases to Evaluate AIDS–South-
ern Africa (IeDEA-SA) collaboration to estimate mortality for up
to 3 y of follow-up associated with starting ART at a range of
different CD4 values in children aged 2–5 y. Our primary study
aim was to determine whether there is any difference in estimated
mortality associated with starting ART at the World Health
Organization (WHO) 2010 recommended threshold of CD4 count
,750 cells/mm3 or CD4% ,25% [16] in comparison to starting
ART immediately as recommended in the WHO 2013 guidelines.
Methods
Ethics Statement
The IeDEA-SA collaboration study was approved by the
University of Cape Town and University of Bern human research
ethics committees. The requirement for informed consent was
waived, as only anonymized data that were already collected as
part of routine monitoring contributed to the collaborative dataset.
Cohort Description and Selection of Children
This study is based on HIV treatment cohorts in southern Africa
that took part in the IeDEA-SA collaboration (http://www.iedea-
sa.org/). The collaboration has been described in detail elsewhere
[17,18]. In brief, data were collected at each site as part of routine
monitoring and were transferred to data centres at the University
of Cape Town, South Africa, or the University of Bern,
Switzerland, at regular intervals. All programmes obtained ethical
approval from the relevant local institutions before contributing
anonymized patient data to IeDEA-SA. The present analysis is
restricted to eight cohorts that routinely captured both pre-ART
data and post-ART data of HIV-infected children: Lighthouse
Trust Clinic in Malawi; Newlands Clinic in Zimbabwe; and
McCord Hospital, Harriet Shezi Children’s Clinic, Gugulethu
Community Health Centre, Khayelitsha ART Programme,
Hlabisa HIV Treatment and Care Programme, and Rahima
Moosa Mother and Child Hospital in South Africa. All clinics
except McCord Hospital were public health sector programmes
with research support providing primary care to urban popula-
tions, but rural populations were included in the Hlabisa HIV
Treatment and Care Programme [18]. At Harriet Shezi
Children’s Clinic and Rahima Moosa Mother and Child Hospital,
secondary and tertiary care are available in addition to primary
care.
In South Africa, the recommended first-line regimen was two
nucleoside reverse transcriptase inhibitors plus either lopinavir/
ritonavir (children ,3 y of age or ,10 kg) or efavirenz (children
.3 y of age and .10 kg). In Malawi and Zimbabwe the
recommended first-line regimen for all children was two nucleo-
side reverse transcriptase inhibitors plus nevirapine. The nucleo-
side reverse transcriptase inhibitors used were mainly stavudine or
zidovudine plus lamivudine.
All children who were at least 24 mo of age at enrolment into
HIV care, enrolled between 1 January 2000 and 30 June 2012,
and were not older than 60 mo were included. Children who were
not ART-naı¨ve at their time of entry into the HIV care
programmes or who had no follow-up data were excluded from
the analysis. The detailed process of selection of children eligible
for this analysis is provided in Figure 1.
Variable Definitions and Loss to Follow-Up
Baseline characteristics included CD4 count, CD4%, weight-
for-age z-score (WAZ), and height-for-age z-score (HAZ), as well
as the child’s sex and age at first visit. All z-scores were calculated
using WHO standards [19]. Follow-up data consisted of CD4
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count, CD4%, and WAZ, evaluated 1 mo after the first clinic visit
and in 3-mo intervals starting 3 mo after the first visit, for up to
36 mo in care. If two or more observations per interval were
available, the one closest to the middle of the interval was used.
The date of ART initiation (if applicable) was captured as well. If
there were no data for a child in a particular time interval, data
Figure 1. Flowchart: selection of patients.
doi:10.1371/journal.pmed.1001555.g001
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were defined to be missing. The outcome was mortality and was
ascertained by the individual cohorts. Children were defined as
being lost to follow-up (LTFU) and were censored if they had no
contact with their health care facility for 9 mo before database
closure (visits are scheduled up to 6 mo apart and clinic visits being
delayed for up to 3 mo are possible).
Multiple Imputation of Missing Baseline and Follow-Up
Data
To account for missing follow-up data for CD4 count, CD4%,
and WAZ, a child’s last observation was carried forward for a
maximum of 9 mo. For the remaining missing follow-up data, as
well as missing baseline data for CD4 count, CD4%, WAZ, and
HAZ, longitudinal multiple imputation by means of the expectation
maximisation bootstrap algorithm [20] was used to create ten
imputed datasets. Imputations were utilised only after 9 mo without
any visit data, as from there on it is plausible that CD4/WAZ
measurements that determine treatment assignment were taken
(and are thus needed to adjust for time-dependent confounding) but
not electronically recorded, probably because of administrative or
clerical errors. The missing at random assumption is therefore likely
to hold. The imputation model included all measured baseline and
follow-up variables, mortality, follow-up time, a variable indicating
which observations were carried forward, and the region (Zim-
babwe, Malawi, South Africa urban, South Africa rural). The
longitudinal structure of the data was explicitly considered in the
expectation maximisation bootstrap algorithm, nonlinear time
trends were allowed, and lag and lead variables of CD4 count,
CD4%, and HAZ were added to the imputation model. All results
of the multivariate analysis are based on the imputed datasets and
were combined using Rubin’s rules [21].
Statistical Analyses
Baseline characteristics were described using proportions or
medians (reported with first; third quartile) overall and for different
ART initiation thresholds. Follow-up data were described at
12 mo and 24 mo after the first clinic visit.
We then estimated mortality over 3 y of follow-up for ART
initiation at different CD4 thresholds using causal modelling (g-
computation) [13], adjusting for time-dependent confounding of
CD4%, CD4 count, and WAZ, with 95% bootstrap confidence
intervals based on 200 bootstrap samples. WAZ served as a proxy
variable for WHO stage, which was not routinely available in our
data: many clinical events that define advanced clinical WHO
stage, and thus disease progression and severity, relate to a child’s
WAZ—for example, malnutrition, tuberculosis, persistent diar-
rhoea, severe wasting, recurrent bacterial pneumonia, recurrent
bacterial infection, candidiasis, and chronic lung disease [22–24].
WAZ was therefore expected to approximately adjust for the time-
dependent confounding induced by stage-defining severe clinical
events. The analysis was also adjusted with respect to baseline
CD4 count, CD4%, WAZ, HAZ, sex, age, and region.
The primary comparison we considered was (i) giving ART
immediately irrespective of CD4 criteria or (ii) deferring ART until a
child’s CD4 cell count falls below 750 cells/mm3 or CD4% falls
below 25%; further strategies we considered were (iii) deferring ART
until the threshold of CD4 count,500 cells/mm3 or CD4%,20%
is reached, (iv) deferring ART until the threshold of CD4 count,250
cells/mm3 or CD4% ,15% is reached, and (v) no ART is given.
The details of our g-computation algorithm are contained in
Box 1. Briefly, the observed associations in the data were used to
simulate and evaluate counterfactual datasets that would have
been observed under each of the above initiation rules. This
mimics an RCT that compares the effect of the different initiation
rules. These datasets were standardised with respect to the time-
dependent confounders (CD4 count, CD4%, WAZ) that influence
both mortality and ART initiation in children [25]. To implement
this, we first modelled the association of these time-dependent
confounders at all follow-up visits (at time t = 1, 3, 6,… mo) with
disease progression history (follow-up data at time t21), baseline
characteristics (CD4 count, CD4%, WAZ), demographics (age,
sex, region), and ART (at time t21, included under an intention to
treat assumption) using additive linear models. We used additive
logistic regression to model the association of death with the same
variables at each follow-up interval. For all these models nonlinear
relationships and interactions with baseline characteristics were
explored and included if they improved the generalised cross-
validation score. In the second step we used the observed baseline
data and predictions of the fitted models under a specific treatment
initiation rule to simulate the time-dependent confounders and the
outcome ‘‘forward in time’’. These two steps were repeated for all
the above specified ART initiation rules, and mortality in the
simulated datasets was evaluated thereafter. All these steps were
repeated for all bootstrap samples in each imputed dataset and
combined appropriately.
We further conducted a sensitivity analysis, linking data from
three of the South African cohorts (Hlabisa HIV Treatment and
Care Programme, Khayelitsha ART Programme, McCord Hospi-
tal) with the national vital registry to obtain the vital status of
children LTFU. We then imputed remaining events and survival
times for children LTFU and unascertained [26] and estimated
mortality using the g-computation algorithm described above.
We also calculated the percentage of children who presented with
CD4 count above the threshold of 750 cells/mm3 or CD4% above
25% and estimated the probability of falling below one of these
thresholds during the 3 y of follow-up using the Kaplan-Meier
estimator. This analysis was restricted to pre-ART data, and we
censored both children who died and children who were LTFU.
The same probability was also estimated by means of cumulative
incidence functions treating ART initiation, death, and LTFU as
competing events. All analyses were conducted using R 2.15 [27].
Results
From all 15,852 children in the database, there were 3,654
children in the eligible age range from cohorts with regular pre-
ART data capturing. Of these, 110 children who were not ART-
naı¨ve and 610 ART-naı¨ve children with no follow-up data were
excluded. Most of the 2,934 children included in the study were
from South Africa (85%; Figure 1). Median follow-up duration was
928 d (first; third quartile: 314; 1,082), during which 2,227 (75.9%)
children started ART. In total there were 83 recorded deaths; 30 of
these (36.1%) occurred in the first 3 mo, 40 (48.2%) in the first
6 mo. Overall, 662 (22.6%) children were defined to be LTFU.
The median (first; third quartile) age at enrolment into HIV
care was 3.3 y (2.6; 4.1), and 1,501 (51.2%) were male (Table 1).
The median CD4 count at enrolment was 592 cells/mm3 (356;
895), median CD4% was 16% (10; 23), and median WAZ and
HAZ were 21.4 (22.3; 20.5) and 22.6 (23.5; 21.6), respec-
tively. Among those who initiated ART, 1,716 (77%) started with
a CD4 count below 750 cells/mm3 or CD4% below 25%, and 100
(4.5%) with a CD4 count above 750 cells/mm3 or CD4% above
25%. For 411 (18.5%) children, CD4 values at ART initiation
were not available. The 707 (24.1%) children who never initiated
ART had higher median CD4 count, CD4%, HAZ, and WAZ at
their first clinic visit than children who initiated ART late (for
example, at CD4 count below 750 cells/mm3 or CD4% below
25%) during follow-up. Among children who initiated ART, those
When to Start ART in Children Aged 2–5 Years
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who had lower CD4 counts or CD4% at ART initiation also had
lower CD4 counts (and CD4%, WAZ, HAZ) at their first clinic
visit (Table 1). Children who started ART had large CD4 and
WAZ gains, up to .100%, compared to their first visit when
presenting with a CD4 count below 250 cells/mm3 or CD4%
below 15% at ART start (Table 2). The characteristics of children
at enrolment were overall similar for the different cohorts, though
there was some variation with respect to the median CD4 count
(between 528 and 734 cells/mm3) and median WFA (between
20.9 and 21.8) (Table 3).
The results of the g-computation analysis provided higher
mortality point estimates for initiating ART at lower CD4 values
Box 1. Details of the g-Computation Algorithm
Step 1: Model fitting. For the 3-y period of follow-up we
considered the follow-up times t= 0, 1, 3, 6, 9,…, 36 mo
after the first clinic visit.
(a) Time-dependent confounders. We used additive linear
models to estimate the association of the time-dependent
confounders (CD4 count, CD4%, WAZ) with
N disease progression history (CD4 count, CD4%, and
WAZ at time t21)
N baseline characteristics (CD4 count, CD4%, WAZ, HAZ)
N demographics (age, sex, region)
N the intervention (ART at time t21)
(a) for t = 1, 3, 6,…, 36 mo. This corresponds to fitting three
models (corresponding to the three time-dependent con-
founders) for 12 points in time.
(b) Outcome. We used a logistic additive model to estimate the
association of the outcome (death) with the time-dependent
confounders at time t, disease progression history, baseline
characteristics, demographics, and intervention for t = 1, 3,
6,…, 36 mo. This corresponds to fitting one model for
12 points in time.
(c) Model building. The models were built as follows:
(i) CD4 count was square root transformed in the models
where CD4 count was the outcome variable.
(ii) Generalized-cross-validation-based model selection en-
sured a good bias–variance tradeoff of the models.
(iii) Nonlinear interactions of continuous variables (both
time-dependent and baseline) with baseline characteris-
tics (represented in categories) were explored to allow for
flexible disease progression depending on how sick
children present at their first visit. They were included
if it improved the generalized cross-validation score of
the model.
(iv) The effect of continuous variables on the outcomes was
modelled in a nonlinear manner via p-splines. The
complexity of the splines was determined by means of
generalized cross-validation.
Step 2: Simulation. We simulated data for the children
for one specific intervention forward in time.
At the first visit, t= 0, the data corresponded to the
observed data of all children.
(a) Simulation of the covariates. For t = 1, 3, 6,…, 36 mo, CD4
count at time t was predicted by a random draw from a
normal distribution where mean and standard error were
obtained from the prediction of the additive linear model
fitted in Step 1(a). The additive linear model corresponds to
the model fitted at time t, and the intervention was set as
specified by the treatment rule (e.g., ART = 0 if the
intervention of interest was ‘‘never give ART’’). Prediction
for CD4% and WAZ were obtained in the same manner.
(a) The simulated values of CD4 count, CD4%, and WAZ at
time t21 were used when predicting the CD4 count, CD4%,
and WAZ at time t.
(b) Simulation of the outcome. The hypothetical outcome was
simulated based on a draw from a Bernoulli distribution with
the probability obtained from the logistic additive model
fitted in Step 1(b). Again, as in (a), we artificially set our
dynamic intervention to the value corresponding to the
strategy of interest. If the simulated outcome at time t was
equal to 1 (death), then there was no more follow-up at time
t+1.
Step 3: Estimation of mortality. We estimated the
relative mortality for t= 1, 3, 6,…, 36 mo in evaluating our
simulated dataset created in Step 2.
Step 4: Intervention repetitions. We repeated Steps 2
and 3 for all interventions of interest. These interventions
are the following:
(i) Give a child ART immediately, irrespective of his/her
CD4 count and CD4%
(ii) Give a child ART when his/her absolute CD4 count
falls below 750 cells/mm3 or his/her CD4% falls below
25%
(iii) Give a child ART when his/her absolute CD4 count
falls below 500 cells/mm3 or his/her CD4% falls below
20%
(iv) Give a child ART when his/her absolute CD4 count
falls below 250 cells/mm3 or his/her CD4% falls below
15%
(v) Never give a child ART
Step 5: Bootstrap repetitions. We repeated steps 1 to 4
for 200 bootstrap samples. The bootstrapping was utilized
to obtain confidence intervals. The bounds of the 95%
confidence intervals were set at the 2.5th and 97.5th
percentiles of the distribution of the bootstrap estimates.
Step 6: Multiple imputation. Steps 1 to 5 were
repeated for ten imputed sets of data. The multiple
imputation was utilized with the Amelia II package in R.
The imputation model included all measured variables and
explicitly accounted for the longitudinal structure of the
data.
Diagnostics. Imputation diagnostics (comparing imputed
and observed densities, overimputation, convergence of
expectation maximization chains, and time-series plots
[41]) were evaluated to ensure the convergence of the
algorithm and the appropriateness of the imputations.
When to Start ART in Children Aged 2–5 Years
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or not initiating ART at all (Table 4). This pattern became evident
from 2 y after the first visit onwards. There was no mortality
difference between initiating ART immediately, irrespective of CD4
values, or starting ART according to the WHO 2010 threshold of
CD4 count ,750 cells/mm3 or CD4% ,25%: estimates of
cumulative mortality after 3 y of follow-up were 2.1% (95% CI:
1.3%–3.5%) and 2.2% (95% CI: 1.4%–3.5%), respectively. Figure 2
illustrates these estimates in detail, highlighting the almost identical
estimated cumulative mortality (and 95% confidence intervals) for
both ART initiation rules during the entire follow-up period.
The sensitivity analysis included 851 patients, 245 of whom were
LTFU. We were able to link 32 (13.1%) patients LTFU to vital
registration data for the Hlabisa HIV Treatment and Care Programme,
Khayelitsha ART Programme, and McCord Hospital cohorts, and
found three to be dead (one per cohort). After 3 y of follow-up the
percentage of children who died was estimated as 6% (95% CI: 4.7%–
7.4%) for children who received ART immediately irrespective of
their CD4 count, 5.9% (95% CI: 4.6%–7.4%) for children starting
ART at CD4 count ,750 cells/mm3 or CD4% ,25%, and 7.8%
(95% CI: 5.1%–10.4%) for children receiving no ART at all.
When considering the pre-ART data of the 322 children (11%
of all children) who presented with a CD4 count above 750 cells/
mm3 and CD4% above 25%, an estimated 26.0% (95% CI:
20.4%–32.7%) fell below this threshold after 1 y, 54.5% (47.2%–
62.2%) after 2 y, and 72.2% (64.3%–79.6%) after 3 y (Figure 3A).
The estimated probabilities of falling below the threshold were
slightly higher when ART initiation, death, and LTFU were
treated as competing events (Figure 3B).
Discussion
Statement of Principal Findings
Our results indicate no mortality difference for up to 3 y between
immediate ART initiation irrespective of CD4 values and deferred
ART initiation using a CD4 threshold of CD4 count ,750 cells/
mm3 or CD4% ,25%, though point estimates for mortality were
higher when ART was initiated at lower CD4 values (or not at all).
Strengths of the Study
To our knowledge, this is the first attempt to estimate the effect
on mortality of starting ART at different CD4 values in children
aged 2–5 y. Both RCTs and previous causal modelling studies of
observational data included a wider age range of children, with
relatively small numbers of children in the 2–5-y age group
[6,9,28,29]. Although post hoc subgroup analyses of the RCT data
restricted to this age range have been conducted, results were
inconclusive [30]. Moreover, the observational studies had few
children without either clinically or immunologically severe disease
and did not compare different CD4 thresholds but rather
concentrated on the effect of ART itself [28,29].
Table 2. Evolution of CD4 count, CD4 percentage, and weight-for-age z-score over time from enrolment by ART initiation
threshold, reported as median (first; third quartile).
Patient Characteristics (Stratified by CD4
Count/CD4% Threshold for ART) Follow-Up Time
0 mo 12 mo 24 mo
CD4 count
No ART 822 (547; 1,124) 923 (641; 1,192) 817 (634; 1,111)
ART at ,250 cells/mm3 or ,15% 411 (228; 638) 675 (422; 1,034) 869 (575; 1,209)
ART at ,500 cells/mm3 or ,20% 665 (476; 910) 869 (568; 1,288) 967 (663; 1,370)
ART at ,750 cells/mm3 or ,25% 827 (661; 1,138) 1,007 (733; 1,336) 1,029 (721; 1,457)
ART at .750 cells/mm3 and .25% 1,107 (869; 1,426) 1,284 (1,055; 1,643) 1,303 (1,081; 1,787)
Unknown 549 (310; 819) 846 (618; 1,191) 1,009 (720; 1,356)
Total 592 (356; 895) 814 (526; 1,170) 922 (639; 1,288)
CD4%
No ART 23.9 (17.9; 29.2) 26.1 (21.0; 31.8) 26.7 (21.8; 33.6)
ART at ,250 cells/mm3 or ,15% 11.0 (7.4; 14.3) 18.0 (12.6; 24.3) 24.0 (18.2; 29.9)
ART at ,500 cells/mm3 or ,20% 18.0 (16.6; 20.8) 24.0 (19.5; 30.0) 27.0 (21.6; 34.0)
ART at ,750 cells/mm3 or ,25% 22.6 (20.5; 25.0) 26.0 (22.0; 31.9) 28.3 (23.0; 37.0)
ART at .750 cells/mm3 and .25% 28.5 (25.5; 30.6) 30.7 (27.6; 37.9) 34.8 (30.2; 41.9)
Unknown 18.0 (10.4; 24.2) 24.0 (18.5; 30.2) 28.8 (22.7; 35.0)
Total 16.0 (10.3; 23.0) 22.0 (15.8; 28.3) 26.0 (20.9; 32.5)
WAZ
No ART 21.12 (22.07; 20.30) 20.62 (21.28; 0.08) 20.47 (21.08; 0.20)
ART at ,250 cells/mm3 or ,15% 21.46 (22.45; 20.63) 21.00 (21.72; 20.31) 20.84 (21.54; 20.21)
ART at ,500 cells/mm3 or ,20% 21.15 (22.08; 20.39) 20.90 (21.68; 20.19) 20.89 (21.46; 20.19)
ART at ,750 cells/mm3 or ,25% 21.27 (22.07; 20.24) 20.86 (21.60; 20.19) 20.73 (21.56; 0.05)
ART at .750 cells/mm3 and .25% 21.42 (22.25; 20.70) 20.96 (21.71; 20.37) 20.99 (21.50; 20.55)
Unknown 21.65 (22.63; 20.86) 21.02 (21.60; 20.27) 20.81 (21.41; 20.25)
Total 21.37 (22.32; 20.52) 20.93 (21.64; 20.25) 20.80 (21.48; 20.15)
doi:10.1371/journal.pmed.1001555.t002
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Our analysis included a large dataset of nearly 3,000 children
with relatively long follow-up from three resource-limited coun-
tries with high HIV burden. Because of the good availability of
CD4 and WAZ data, which is unusual in this setting, as well as
the use of g-computation, we were able to adjust for measured
time-dependent confounding of CD4 count, CD4%, and WAZ. In
addition, we accounted for missing data using multiple imputation.
The use of a causal modelling technique was essential to
accurately estimate mortality associated with starting ART at
different CD4 values in the presence of time-dependent confound-
ing by indication, whereby the illest children have the greatest risk of
mortality and are also most likely to be started on ART. There was
clear evidence for time-dependent confounding: a naı¨ve analysis of
the data simply adjusting for demographic and disease severity
characteristics at enrolment showed that ART initiation was
associated with higher mortality than no ART initiation (hazard
ratio = 1.80; 95% CI: 1.03–3.15). Other causal modelling tech-
niques such as inverse probability of treatment weighting, g-
estimation, or targeted maximum likelihood estimation could also
have been used to derive results that adjust for time-dependent
confounding, though g-computation is probably the most intuitive
when dealing with dynamic treatment comparisons [13].
Limitations
Although we used causal modelling, this analysis is based on
observational data, and the results may be affected by residual
confounding. For example, WHO clinical stage data were not
routinely available throughout follow-up, and so we may not have
adequately adjusted for the effect of clinical disease severity. We
addressed this possibility by adjusting for WAZ, which is a
surrogate of disease severity and should at least partly capture
staging information [23]. Some stage-defining events such as HIV
encephalopathy or HIV-associated nephropathy may, however,
not be reflected by WAZ.
When interpreting estimates of mortality associated with
starting ART at high CD4 values, it should be noted that
relatively few children initiated ART before their CD4 count or
CD4% declined. Since country and WHO guidelines at the time
Figure 2. Estimated cumulative mortality for immediate versus deferred ART. Estimated cumulative mortality (including 95% bootstrap CI,
dashed lines) over 3 y if ART was given irrespective of CD4 count and CD4% (blue line, ‘‘always ART’’) and if ART was given if the CD4 count was
below 750 cells/mm3 or the CD4% was below 25% (red line, ‘‘750,25%’’).
doi:10.1371/journal.pmed.1001555.g002
Table 4. Estimated mortality (and 95% bootstrap confidence intervals) after 1, 2, and 3 y of follow-up for different initiation
strategies.
Threshold Years of Follow-Up
1 y 2 y 3 y
No ART 1.7% (0.9%–3.2%) 2.8% (1.7%–6.0%) 3.4% (2.1%–6.5%)
ART if CD4 count ,250 cells/mm3
or CD4% ,15
1.4% (0.8%–2.3%) 2.2% (1.4%–3.8%) 2.5% (1.6%–4.1%)
ART if CD4 count ,500 cells/mm3
or CD4% ,20
1.4% (0.8%–2.3%) 2.1% (1.3%–3.2%) 2.3% (1.4%–3.5%)
ART if CD4 count ,750 cells/mm3
or CD4% ,25
1.4% (0.8%–2.3%) 1.9% (1.2%–3.2%) 2.2% (1.4%–3.5%)
ART irrespective of CD4 count 1.4% (0.7%–2.3%) 1.9% (1.1%–3.2%) 2.1% (1.3%–3.5%)
doi:10.1371/journal.pmed.1001555.t004
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did not recommend ART initiation at high CD4 values unless
children had WHO clinical stage 3 or 4 disease, it is plausible that
these children may have initiated therapy on the basis of advanced
clinical disease. The median WAZ in children starting ART with
CD4 .750 cells/mm3 or CD4% .25% was 21.42 (Table 1),
indicating that a proportion of these children had clinically severe
disease. Our analysis may therefore underestimate mortality
reductions associated with starting ART at high CD4 values in a
child without symptomatic disease. Nevertheless, our mortality
estimates associated with immediate ART initiation or starting
ART at a high CD4 value are consistent with the probability of
experiencing AIDS or death found in both the immediate and
deferred ART arms of the PREDICT trial [9]. It would be useful
to repeat this analysis using data from other settings, for example,
in high-income settings where more children start ART earlier in
the course of their disease.
Further limitations of our study include not examining
outcomes beyond 3 y of follow-up. This limitation is especially
relevant with respect to evaluating toxicity risk and the effect of
development of resistance in a context of limited second-line
options. In addition, children included in our study were mostly
from urban settings with facilities for electronic data collection in
southern Africa, especially from South Africa. Generalisability to
rural areas and sub-Saharan African countries with less well-
resourced health care systems may be limited. In addition,
country-specific differences regarding drug regimens, public health
programmes, and breastfeeding [31] and its implications for the
timing of HIV infection may contribute to both mortality figures
and the success of different treatment strategies.
Our analysis was specifically targeted at examining the WHO
2010 guidelines for ART initiation for children aged 2–5 y and
how mortality would be affected by the WHO 2013 guideline
recommendations. There are, however, other interesting compar-
isons that remain unexplored: for example, we did not include
children between 1 and 2 y of age. There are currently no data
that show mortality benefits of early ART in this age group [3]; a
comparison with the age groups in this analysis would therefore be
useful.
Mortality Estimates in Context
The absolute mortality estimates for all ART initiation strategies
in our study are relatively low [10,28]. This finding may partly be
explained by the analysis being restricted to children aged at least
2 y at their first visit to an HIV care and treatment facility. Our
data therefore comprise a cohort of survivors who have not died
and have not been referred for HIV care or ART prior to reaching
2 y of age, and so may have less rapidly progressing disease
[10,11,32]. However, it is precisely in this group of children that
the optimal timing of ART initiation needs to be determined, as
WHO 2010 guidelines already recommend immediate ART in
children presenting at less than 2 y of age [16]. Moreover, our
mortality estimates are comparable to the results of the PREDICT
trial, which reported a 2.1% and 1.3% risk of death/AIDS events
after 144 wk in the early and deferred ART arms, respectively [9].
We may still have underestimated mortality. Children with no
visits after enrolment were excluded from the analysis, as at least
one follow-up visit is needed in order for children to have the
possibility to initiate ART and thus allow the implementation of
our methodology. The excluded children had higher CD4 counts
(median [first; third quartile]: 694 cells/mm3 [382; 1,073]) and
CD4% values (median [first; third quartile]: 21% [13%; 28%]) but
lower WAZ values (median [first; third quartile]: 21.9 [20.7;
23.3]), and their mortality may be different from those included in
the analysis.
Figure 3. Estimated probability of falling below a CD4 count of
750 cells/mm3 or a CD4 percentage of 25%. (A) Time to fall below
the CD4 threshold of a CD4 count of 750 cells/mm3 or a CD4% of 25%
estimated via the Kaplan-Meier estimator. The figure is based on 322
children presenting with a CD4 count of 750 cells/mm3 or above and a
CD4% of 25% or above. Only pre-ART follow-up is considered. 95%
confidence intervals are visualised via the grey shaded area. (B) Time to
fall below the CD4 threshold of a CD4 count of 750 cells/mm3 or a CD4%
of 25%. The figure is based on 322 children presenting with a CD4 count
of 750 cells/mm3 or above and a CD4% of 25% or above. ART initiation,
death, and LTFU were treated as competing risks. The probability of
falling below the threshold was estimated via the cumulative incidence
of falling below the threshold before any other event occurred divided by
one minus the probability that any other event occurred before the
threshold was reached. 95% confidence intervals were obtained via
bootstrapping and are visualised via the grey shaded area.
doi:10.1371/journal.pmed.1001555.g003
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In addition, among the 2,934 children included in the analysis,
those LTFU were censored at their last visit, and mortality may
also be higher among those LTFU compared to those remaining
in care [18,33,34]. To address this potential problem we
conducted a sensitivity analysis, linking data from three of the
South African cohorts with the national vital registry and imputing
survival times and events of children LTFU and unascertained
with multiple imputation as described previously [26]. This
analysis confirmed that mortality might be higher than reported,
though the relative differences between the strategies in the
sensitivity analysis after 3 y of follow-up remained similar to those
in our initial results ignoring LTFU that yielded much lower
mortality estimates. It is worth mentioning that our estimate of
mortality for children receiving no ART (7.8% [95% CI: 5.1%–
10.4%]) is consistent with estimates of mortality from previous
studies among children in this age group in the absence of ART
[10]. However, the linkage information we had was sparse, the
sample size was small, and data were available only from South
Africa, so mortality estimates derived after linking data with the
death registry should be interpreted with caution.
Implications and Considerations for Clinicians and
Policymakers
The WHO guidelines changed in 2013 and now recommend
ART initiation in all children less than 5 y of age irrespective of
clinical or immunological disease severity. Our results suggest that
this change in ART initiation criteria would neither reduce nor
increase mortality. There may, however, be other considerations
regarding the optimal timing of ART. For example, while the
PREDICT trial showed that the immune response to ART was
equivalent in both groups, children in the deferred group spent
more time at a lower CD4 count, which may result in more
chronic inflammation and a higher risk of clinical events. This
consideration is especially important for the older children in our
age group, as their thymic responses are not as good as in children
under 2 y [35]. However, there was no difference in the number of
CDC category B or C events between the two arms in the
PREDICT trial [8,9]. The long-term effects of earlier ART
initiation on immune function, growth, neurological development,
toxicity, and development of resistance remain to be explored. In
addition, maintaining long-term adherence can be particularly
challenging in young children because of the need for a caregiver
to administer medication and possible caregiver changes, lack of
child-friendly formulations, and the need for frequent dose
changes in growing children.
Programmatically it may be simpler to have a single treatment
initiation approach for all children ,5 y of age that does not
require regular pre-ART follow-up and CD4 measurement,
especially in settings where access to CD4 measurement is limited
[36]. Coordination of recommended regimen choices with age
thresholds for starting ART would also ease implementation. In
our study only about 11% of children aged 2–5 y had CD4 count
.750 cells/mm3 and CD4% .25% at presentation, and we
estimated 72.2% (see Figure 3A) to have progressed below these
values within 3 y, though the proportion might be even larger
during early follow-up, given that children who were censored
because they were LTFU or started ART may have had faster
disease progression than others. Deferring treatment until CD4
count drops below 750 cells/mm3 or CD4% drops below 25%
may not delay the onset of therapy very much, and may risk a
child becoming LTFU and/or not having his/her repeat CD4
measured, thus not starting on treatment promptly after dropping
below the initiation threshold. However, it would be important to
ensure that immediate ART initiation in children aged 2–5 y does
not happen at the expense of prioritising early infant diagnosis and
rapid initiation, which has been shown to reduce mortality but
may be more challenging to implement. This consideration is
especially important in resource-limited settings, where an
increasing number of patients often overburdens health care
facilities, and clinics are therefore not able to trace children who
miss their infant diagnostic testing and results or CD4 testing
appointments [37,38].
It has also been suggested that early ART initiation may reduce
the high loss to follow-up frequently observed in pre-ART care
[39]. However, loss to follow-up has not consistently been shown
to be lower in children commenced on ART compared to those
not on ART [40]. In addition, there may be selection bias, as
children more likely to remain in care are more likely to get started
on therapy.
Conclusion
Our results indicate that in children aged 2–5 y in southern
Africa, there is no difference in mortality between starting ART
immediately and deferring until CD4% drops below 25% or CD4
count drops below 750 cells/mm3. The overall clinical and
programmatic implications of earlier ART initiation, such as effects
on morbidity-related outcomes, retention in care, cost-effectiveness,
adherence, and drug resistance, remain to be explored.
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Editors’ Summary
Background. Infection with HIV, the virus that causes AIDS,
contributes substantially to the burden of disease in children.
Worldwide, more than 3 million children younger than 15
years old (90% of whom live in sub-Saharan Africa) are HIV-
positive, and every year around 330,000 more children are
infected with HIV. Children usually acquire HIV from their
mother during pregnancy, birth, or breastfeeding. The virus
gradually destroys CD4 lymphocytes and other immune
system cells, leaving infected children susceptible to other
potentially life-threatening infections. HIV infection can be
kept in check, with antiretroviral therapy (ART)—cocktails of
drugs that have to be taken daily throughout life. ART is very
effective in children but is expensive, and despite concerted
international efforts over the past decade to provide
universal access to ART, in 2011, less than a third of children
who needed ART were receiving it.
Why Was This Study Done? For children diagnosed as
HIV-positive between the ages of two and five years, the
2010 World Health Organization (WHO) guidelines for the
treatment of HIV infection recommended that ART be
initiated when the CD4 count dropped below 750 cells/
mm3 blood or when CD4 cells represented less than 25% of
the total lymphocyte population (CD4 percent). Since June
2013, however, WHO has recommended that all HIV-positive
children in this age group begin ART immediately, irrespec-
tive of their CD4 values. Earlier ART initiation might reduce
mortality (death) and morbidity (illness), but it could also
increase the risk of toxicity and of earlier development of
drug resistance. In this causal modeling analysis, the
researchers estimate the mortality associated with starting
ART at different CD4 thresholds among children aged 2–5
years using observational data collected in cohort studies of
ART undertaken in southern Africa. Specifically, they com-
pared the estimated mortality associated with the WHO 2010
and WHO 2013 guidelines. Observational studies compare
the outcomes of groups (cohorts) with different interven-
tions (here, the timing of ART initiation). Data from such
studies are affected by time-dependent confounding: CD4
count, for example, varies with time and is a predictor of
both ART initiation and the probability of death. Causal
modeling techniques take time-dependent confounding into
account and enable the estimation of the causal effect of an
intervention on an outcome from observational data.
What Did the Researchers Do and Find? The researchers
used g-computation (a type of causal modeling) adjusting
for time-dependent confounding of CD4 percent, CD4 count,
and weight-for-age z-score (a measure of whether a child is
underweight for their age that provides a proxy indicator of
the clinical stage of HIV infection) to estimate mortality for
ART initiation at different CD4 thresholds in 2,934 ART-naı¨ve,
HIV-positive children aged 2–5 years old at their first visit to
one of eight study sites in southern Africa. The average initial
CD4 values of these children were a CD4 count of 592 cells/
mm3 and a CD4 percent of 16%. The estimated cumulative
mortality after three years was 3.4% in all children if ART was
never started. If all children had started ART immediately
after diagnosis irrespective of CD4 value or if the 2010 WHO-
recommended threshold of a CD4 count below 750 cells/
mm3 or a CD4 percent below 25% was followed, the
estimated cumulative mortalities after three years were 2.1%
and 2.2%, respectively (a statistically non-significant differ-
ence).
What Do These Findings Mean? These findings suggest
that, among southern African children aged 2–5 years at HIV
diagnosis, there is no difference in mortality for up to three
years between children in whom ART is initiated immediately
and those in whom ART initiation is deferred until their CD4
value falls below a CD4 count of 750 cells/mm3 or a CD4
percent of 25%. Although causal modeling was used in this
analysis, the accuracy of these results may be affected by
residual confounding. For example, the researchers were
unable to adjust for the clinical stage of HIV disease at HIV
diagnosis and instead had to use weight-for-age z-scores as a
proxy indicator of disease severity. Other limitations of the
study include the large number of children lost to follow-up
and a possible lack of generalizability—most of the study
participants were from urban settings in South Africa.
Importantly, however, these findings suggest that the recent
change in the WHO guidelines for ART initiation in young
children is unlikely to increase or reduce mortality, with the
proviso that the long-term effects of earlier ART initiation
such as toxicity and the development of resistance to ART
need to be explored further.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001555
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N NAM/aidsmap provides basic information about HIV/AIDS
and summaries of recent research findings on HIV care and
treatment
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including informa-
tion on HIV and AIDS in Africa and on children and HIV/
AIDS (in English and Spanish)
N The UNAIDS World AIDS Day Report 2012 provides up-to-
date information about the AIDS epidemic and efforts to
halt it; the 2013 Progress Report on the Global Plan provides
information on progress towards eliminating new HIV
infections among children by 2015
N The World Health Organization provides information about
universal access to AIDS treatment (in several languages);
its 2010 guidelines for ART in infants and children and its
2013 consolidated guidelines on the use of ART can be
downloaded
N The researchers involved in this study are part of the
International Epidemiologic Databases to Evaluate AIDS–
Southern Africa collaboration, which develops and imple-
ments methodology to generate the large datasets needed
to address high-priority research questions related to HIV/
AIDS
N Personal stories about living with HIV/AIDS, including
stories from young people infected with HIV, are available
through Avert, through NAM/aidsmap, and through the
charity website Healthtalkonline
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